Navigation Links
TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
Date:3/26/2008

LA JOLLA, Calif., March 26 /PRNewswire-FirstCall/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced financial results for the fourth quarter and year ended December 31, 2007. For the full year 2007, the Company posted revenue of $9.9 million and a net loss of $23.4 million. Cash and cash equivalents totaled $32.5 million at December 31, 2007.

"We made meaningful progress in our three clinical development programs in 2007," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines. "Particularly noteworthy was the successful completion of our Phase IIb clinical trial that demonstrated that tezampanel relieved migraine pain at a dose that is safe and well-tolerated. We look forward to an End of Phase II meeting with the FDA to discuss advancing tezampanel into Phase III. In 2008, we are continuing to build a strong clinical platform for our other product candidates: NGX426, our oral glutamate receptor antagonist, and NGX267, our lead M1 agonist, that is currently in a Phase II trial for xerostomia secondary to Sjogren's syndrome."

2007 Highlights:

-- Tezampanel met the primary endpoint at the 40 mg dose in a 306-patient,

Phase IIb clinical trial for the treatment of a single, acute migraine

attack. This is the sixth Phase II trial in which tezampanel has been

shown to have analgesic activity and the second placebo-controlled

trial to establish efficacy for tezampanel as a treatment for acute

migraine. TorreyPines intends to hold an End of Phase II meeting with

the U.S. Food and Drug Administration (FDA) in the second half of 2008

to discuss the scope of a Phase III program with tezampanel for the

treatment o
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
2. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
3. TorreyPines Therapeutics Reports Third Quarter 2007 Results
4. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
6. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
7. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
8. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
9. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
10. Blake M. Paterson MD, CEO and Co-founder of Alba Therapeutics, Wins Greater Baltimore Committee 2008 Leadership in Bioscience Award
11. Cell Therapeutics, Inc. (CTI) Invest Northwest Presentation to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... FALLS, N.Y., Jan. 15, 2014   Niagara Thermal ... been selected by Buffalo BioBlower Technologies LLC ("B3") as ... SBIR Phase 2 award from the Army Corps of ... system that kills all biological contaminants and destroys VOCs ...
(Date:1/15/2014)... Cynvenio, a cancer diagnostics company focused ... analysis of tumor cells in the bloodstream, today announced ... decision support application powered by CollabRx, Inc. , ... test, Therapy Finder will provide breast cancer patients and ...
(Date:1/15/2014)... 2014 ­ RedBrick Health , a fast-growing leader ... announces that EmblemHealth , the New ... now providing the RedBrick Compass health assessment, combined with ... of its members. EmblemHealth is among the first health ...
(Date:1/15/2014)... 2014 A study has been launched to ... 1 track could help to tackle the problem of obesity. ... (a GP surgery based in Stowmarket) and academics at University ... Telemetry technology, which is inspired by equipment used to ...
Breaking Biology Technology:Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4
... Feb. 5 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,Ltd (AXS: PSX; Nasdaq: ... Shareholders on the afternoon of Wednesday 6th February. ... following morning to,review the quarter and answer investor ... (Sydney), on Thursday 7th February,(Wednesday 6thFebruary, at 4.30pm ...
... Blue Cross and Blue Shield of,Texas (BCBSTX) is ... integrated medical-dental program. The program is unique in ... dental data to,create a customized plan aimed to ... specifically help users optimize their overall health by,making ...
... STEWARTVILLE, Minn., Feb. 4 Rochester Medical,Corporation (Nasdaq: ... ending December 31, 2007., The Company reported sales ... the first quarter of last year. It also reported,net ... to a net income,of $31,467,000 or $2.59 per diluted ...
Cached Biology Technology:Blue Cross and Blue Shield of Texas Launches an Integrated Medical-Dental Health Program 2Blue Cross and Blue Shield of Texas Launches an Integrated Medical-Dental Health Program 3Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter 2Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter 3Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter 4Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter 5Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter 6Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter 7
(Date:4/23/2014)... study to date of the family of bacteria ... vaccine strategies and reveals surprising findings about the ... alter public health strategies to control this respiratory ... , Genomic analysis of 343 strains of the ... world collected over the last 100 years illustrates ...
(Date:4/23/2014)... 2014 A biomedical engineer at the University of ... to make blood transfusions safer. His work is supported ... of Health (NIH). , Blood transfusions save millions ... medicine,s absolute necessities. Without them, for instance, routine surgeries ... perfect, however. There,s strong evidence that transfusions of red ...
(Date:4/23/2014)... is leading a 2 million Food Standards Agency (FSA) ... premises and industry workers. , Norovirus outbreaks can ... a batch of frozen strawberries infected 11,000 people in ... understanding of which strains cause infection and which foods ... , Researchers will produce data that will help ...
Breaking Biology News(10 mins):Impact of whooping cough vaccination revealed 2UH biomedical engineer works to make blood transfusions safer 2UH biomedical engineer works to make blood transfusions safer 3
... Major League Baseball pitchers indicates that the height of the ... may lead to potential injuries because of stress on the ... by William Raasch, M.D., associate professor of orthopaedic surgery at ... the head team physician for the Milwaukee Brewers. Major League ...
... a way that had never been observed in any ... Biology, a Cell Press publication. The discoverywhich marks the ... perceive circular polarized light may lend mantis shrimp a ... a new dimension of vision, said Justin Marshall of ...
... Purdue University researchers have identified several soybean varieties that ... Indiana and are resistant to root-knot nematodes, a plant-destroying ... of the state. The researchers verified that resistance ... well the plant will fight off another nematode species, ...
Cached Biology News:Study finds pitching mound height affects throwing motion, injury risk 2Mantis shrimp vision reveals new way that animals can see 2Mantis shrimp vision reveals new way that animals can see 3Soybean varieties viable in southern Indiana, resistant to root-knot nematode 2Soybean varieties viable in southern Indiana, resistant to root-knot nematode 3
Transfection Buffer A & B Set 5 ml each...
Kit contains: Bio-Rad Amplification Reagent, 2x Amplification Diluent, Streptavidin-HRP, Blocking Reagent, and Phosphate Buffered Saline....
Mouse polyclonal antibody to PRDM2 - PR domain containing 2, with ZNF domain...
... 209/ pSer 211 ] affinity isolated antibody ... phosphate buffered saline (without Mg 2+ and ... BSA (IgG and protease free) and 0.05% sodium ... region of mouse Hck that contains tyrosine 207 ...
Biology Products: